Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途

Use of PARP inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

Abstract

在一个实施方案中,本发明涉及一种用于治疗乳腺癌或卵巢癌患者的方法,其包括接收陈述患者的肿瘤展现LOH的测定结果,以及施用PARP抑制剂。在一个实施方案中,本发明包括:如果数据包括i)BRCA1或BRCA2中的一个或多个有害突变,或ii)如通过用各个别LOH区域的长度的总和除以总基因组长度所确定,基因组具有大于10%LOH的百分比,其中LOH区域定义为在多个连续单核苷酸处存在纯合性,但排除整个染色体或染色体臂LOH,则用计算机系统将所述癌症患者分类为可能对PARP抑制剂起响应。
In one embodiment, the subject invention relates to a method for treatment of a breast or ovarian cancer patient that includes receiving assay results stating that the patient's tumor exhibits LOH, and administering a PARP inhibitor. In one embodiment, the subject invention comprising: classifying said cancer patient, with the computer system, as being likely to respond to a PARP inhibitor if the data comprises i) one or more deleterious mutations in BRCA1 or BRCA2, or ii) a percentage of the genome having greater than 10 percent LOH as determined by the sum of the lengths of each individual LOH region divided by the total genome length, wherein an LOH region is defined as the presence of homozygosity at multiple contiguous single nucleotides, but excludes whole chromosome or chromosome arm LOH.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (0)

    Title

Cited By (0)

    Publication numberPublication dateAssigneeTitle